Patent intelligence · US
US 12215133
GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use
GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use
Patent details — US 12215133
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 4, 2025
- Expiration
- Jan 30, 2045
- Claims
- 8
- CPC classes
- A61K, A61K38/00, A61K38/26, A61P
Quick answer
US 12215133 (GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use) is held by BrightGene Bio-Medical Technology Co., Ltd.. Status: granted. Granted Feb 4, 2025. Expires Jan 30, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K38/00, A61K38/26, A61P, A61P3/10
More from BrightGene Bio-Medical Technology Co., Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12383631
Immune antigen specific IL-18 immunocytokines and uses thereof
granted -
US 12350120
Gum-protecting and teeth-whitening strip and preparation method thereof
granted -
US 12220447
Proteolytic enzyme composition
granted -
US 12173062
Modified TNF-α antibodies and uses thereof
granted -
US 12115136
Fortified CBD oil for treatment of PTSD
granted -
US 12097230
Method and composition for treating post operative conditions
granted -
US 11925686
Materials for phototherapies of ophthalmic diseases
granted
Frequently asked questions
What is US patent 12215133?
US 12215133 (GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use) is held by BrightGene Bio-Medical Technology Co., Ltd.. Status: granted. Granted Feb 4, 2025. Expires Jan 30, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12215133?
BrightGene Bio-Medical Technology Co., Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 57 pharmaceutical patents for this assignee.
When does US 12215133 expire?
Our index shows an expiration date of Jan 30, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.